share_log

EF Hutton Initiates Coverage On Citius Pharma With Buy Rating, Announces Price Target of $6

Benzinga ·  Jul 15 09:44

EF Hutton analyst Jason Kolbert initiates coverage on Citius Pharma (NASDAQ:CTXR) with a Buy rating and announces Price Target of $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment